Diabetes and the cardiologists: a call to action∗∗Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.  by Friesinger, Gottlieb C & Gavin, James A
EDITORIAL COMMENT
Diabetes and the Cardiologists:
A Call to Action*
Gottlieb C. Friesinger, II, MD,*
James A. Gavin, III, MD, PhD†
Chevy Chase, Maryland and Nashville, Tennessee
Two articles in this issue of the Journal persuasively empha-
size the importance of diabetes in the long-term outcome of
coronary heart disease (CHD) after revascularization
procedures (1,2). These two randomized controlled trials
comparing coronary artery bypass grafting (CABG) and
See pages 1116 and 1122
percutaneous transluminal coronary angioplasty (PTCA) in
patients with multivessel disease clearly demonstrate the
adverse effects of diabetes. It has long been appreciated that
diabetes is a major risk factor for the development of
atherosclerosis resulting in a wide variety of cardiovascular
dysfunction and complications, including renal disease with
hypertension, diastolic dysfunction, platelet abnormalities,
abnormal vascular reactivity, etc. (3,4). During the last
several decades, other major risk factors, particularly hyper-
tension, smoking and lipid abnormalities have been the
targets for intensive efforts at risk reduction, but diabetes has
received scant specific attention, especially by cardiologists.
In three leading textbooks, pages devoted to diabetes are
limited: 11 of 2,602 (5), 5 of 1,996 (6) and 23 of 2,641 (4)
text pages. The sections devoted to lipid abnormalities and
hypertension each contain many more pages (2 to 10 times
as many). The landmark Diabetes Control and Complica-
tions Trial (DCCT) convincingly demonstrated that fastid-
ious control of blood glucose can delay or prevent compli-
cations in type 1 diabetes mellitus (T1DM) (7). Similar
studies are ongoing in reference to the much more common
type 2 diabetes (T2DM).
The Bypass Angioplasty Revascularization Investigation
(BARI) (1) and Emory Angioplasty vs. Surgery Trial
(EAST) (2) have many similarities in reference to study
design. Both studies enrolled symptomatic patients with
multivessel coronary atherosclerotic disease who were eligi-
ble for either CABG or PTCA as their first revasculariza-
tion procedure. Differences in patient selection and proto-
cols exist but are not critical to the discussion in this
editorial. Emory Angioplasty vs. Surgery Trial is a single
center trial involving 392 patients while BARI enrolled
1,829 patients from 18 centers. The current reports describe
long-term follow-up at seven to eight years after first
intervention. The BARI trial is more informative in refer-
ence to the role of diabetes in the long-term outcome. In
both studies, the long-term follow-up (seven to eight years)
demonstrates that diabetic patients who had PTCA as their
first revascularization procedure had a significantly higher
mortality than nondiabetic patients. There was no signifi-
cant mortality difference related to the choice of first
revascularization procedure in the nondiabetic patients.
The BARI trial involves not only a larger number of
patients but more detailed data, which permits more sophis-
ticated analyses. There was a statistically significant survival
benefit for patients who had CABG as the first procedure
(84.4% vs. 80.9%, p 5 0.043) at the seven-year follow-up.
The entire mortality benefit derives from the drug treated
(oral hypoglycemic or insulin) diabetic patients who consti-
tuted 19.3% of the sample. There was no mortality differ-
ence in the remainder of the patients, nondiabetics and
diabetics not on drug treatment. Coronary artery bypass
grafting resulted in better survival in all a priori subgroups,
which included severity of angina, left ventricular function
and angiographic characterization of vessel disease, includ-
ing number of vessels involved, presence of proximal left
anterior descending artery (LAD) disease and lesion char-
acteristics. Although drug treated diabetic patients had
more severe overall disease than the rest of the patients (and
a poorer outcome regardless of treatment), the randomiza-
tion process assured equal distribution of these more severe
attributes in both the PTCA and CABG treatment arms.
The conclusion is inescapable; diabetes is an independent
determinant of adverse outcome in this trial.
The smaller single center EAST also had a lesser per-
centage of drug-treated diabetic patients, 15%, versus 19.3%
in BARI. The overall eight-year mortality demonstrated no
statistically significant difference relative to the first revas-
cularization procedure selected, but the CABG group had a
better survival (82.7% vs. 79.3%, p 5 0.40). Hence, three
lives would be saved per 100 patients treated if the study had
been powered to detect such a difference statistically. How-
ever, the eight-year survival difference in the 59 drug-
treated diabetic patients (30 in the CABG group and 29 in
the PTCA group) was highly disparate (82.6% in nondia-
betic patients and 60.1% in drug-treated diabetic patients)
and statistically significant (p 5 0.02). The remaining 333
nondiabetic patients demonstrated no difference in survival
relative to initial revascularization procedure selected: 84.9%
in the PTCA group versus 82.6% in the CABG group (p 5
0.7). The difference in mortality in diabetic patients in
reference to the first selected revascularization procedure
was not significantly different at the five-year follow-up
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(although major difference was seen), undoubtedly reflecting
the small number of diabetics in the EAST. This observa-
tion emphasizes the importance of a longer follow-up when
dealing with a small number of patients in a chronic disease.
Unfortunately, in neither study are we given any infor-
mation about how effectively the diabetic patients’ glycemic
state was controlled. It can be assumed this is an important
issue in reference to outcome, especially in light of the
information from the DCCT trial (7).
The approach to catheter-based interventions has
changed in major ways since the EAST and BARI trials
were started more than 10 years ago. Stents, and a variety of
devices, have been introduced and, in many laboratories, are
used in the majority of patients with generally overall
improved outcomes when compared with PTCA. Pharma-
cological therapy with IIb, IIIa glycoprotein receptor antag-
onists are now routine adjunctive therapy and result in
improved procedure outcomes. Ongoing studies will clarify
further how much these newer approaches improve out-
comes in diabetic patients. However, we need not await the
outcome of these (and undoubtedly yet to come) additional
trials to conclude that diabetic patients deserve a much more
assertive approach in recognizing the adverse outcomes
related to the diabetic state (at least if drug therapy is
indicated) and the need for fastidious control of glycemia.
The growing body of evidence in support of decreased
CHD risk and improved outcomes for patient with manifest
disease with better glycemic control in diabetic patients is
compelling. Clinical interventional trials, including the
DCCT (7) and the United Kingdom Prospective Diabetes
Study (UKPDS) (8) have demonstrated that attainment of
average blood glucose of around 150 mg/dl or hemoglobin
A1c (HbA1c) levels of 7.0% result not only in profound
reductions of the microvascular complications of eye, kidney
and nerve disease, but, likewise, results in reductions of
cardiovascular disease risk factors and cardiac event rates.
Additional cross-sectional and epidemiologic studies report
similar findings. Data from Kuusisto et al. (9) in studies on
elderly Finnish patients with T2DM demonstrated that the
lowest CHD mortality and event rates were observed at
HbA1c levels of ,6%, while the highest rates were encoun-
tered at levels .7.9%. Similar relationships between lower
glucose levels and reduced CHD risk were observed in the
Honolulu Heart Study (10) and the Islington Diabetes
Survey (11). A report from the registry portion of the BARI
trial also contains the strong suggestion that overall charac-
teristics of the diabetic patient, including compliance with
treatment, influenced the outcome (12). The principle
emphasized in all of these studies is that aggressive treat-
ment of diabetes with focus on glucose lowering to levels of
HbA1c of #7.0% must assume high priority by cardiolo-
gists, who should feel increasingly obliged to become
involved in the diabetic care of their patients.
It is, unfortunately, not possible to discern how inten-
sively treated the subjects with diabetes were in the BARI
and EAST trials because no HbA1c or other glycemia-
related data were included. It is possible that the outcome
differences might have been muted in the treated diabetics
had their glucose control achieved the currently recom-
mended treatment goals. This is an issue that needs critical
study. It is assumed that diabetic patients not on drug
treatment had less hyperglycemia. They had better out-
comes since they were indistinguishable from nondiabetic
patients; however, we are given no specific information
about the number or characteristics of the diabetic patients
who were not on drug treatment.
It is also clear that control of the hyperglycemic state in
diabetes has a major effect on outcome in the management
of acute myocardial infarction. This is demonstrated in the
Diabetes Mellitus Insulin-Glucose Infusion in Acute Myo-
cardial Infarction (DIGAMI) study (13–15). This Ran-
domized Control Trial of 620 diabetic patients with acute
myocardial infarction evaluated the use of insulin-glucose
infusion to lower blood sugar during the acute phase
followed by prolonged multidose insulin therapy for more
intense post-MI glucose control. The intervention group
had a one-year mortality of 8.6% compared with an 18.0%
one-year mortality in the conventionally treated group. This
is an area of continuing research and interest (16,17). Thus,
the benefits of improved diabetic control are evident from
short-term and long-term interventions.
What now emerges for the cardiologist is the necessity to
accord to the treatment of diabetes the same degree of rigor
and urgency that has been applied to the management of
dyslipidemia and hypertension. It will be just as important
for the cardiologist to understand the pathophysiology of
diabetes as hypertension, especially since both are examples
of insulin-resistant states. However, diabetes must be un-
derstood in terms of the equal importance of insulin
deficiency. It is important to note that insulin deficiency is
the major problem in T1DM and is appropriately treated
with insulin replacement. On the other hand, T2DM is a
dual defect disease, comprising insulin resistance and insulin
deficiency. These differences in underlying pathophysiology
dictate differences in treatment strategies and in the atten-
dant comorbidities. This means that patients with T2DM
must receive treatments directed at both problems. Insulin
resistance is reduced by weight loss and increased physical
activity, which constitute the foundation of treatment for
T2DM, no matter which adjunctive pharmacologic treat-
ments may prove necessary. Knowledge of the underlying
pathophysiology of T2DM makes it possible to select the
pharmacologic treatment more effectively.
The available drugs conveniently target different defects
that contribute to the hyperglycemia of diabetes. The alpha
glucosidases (AGIs) reduce glucose absorption from the gut
and thus lower postprandial hyperglycemia. The thiazo-
lidinediones (TZDs) are insulin sensitizers that increase
tissue sensitivity to insulin, especially muscle and fat, while
the insulin sensitizer metformin is effective in suppressing
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liver glucose production, a source of the excess glucose seen
in persons with diabetes. Metformin also has stimulatory
effects in muscle and has been shown to be especially useful
in overweight T2DM in reducing microvascular disease
events (18). When the beta-cells begin to deteriorate,
usually marked by progressive increases in fasting glucose
despite other oral agent treatment, the secretagogues repa-
glinide or sulfonylureas help restore the sensitivity of the
beta-cell to glucose and, thus, increase insulin release. When
diabetes is diagnosed late, with serious elevations of FPG
already evident, it is often necessary to begin treatment with
an insulin secretagogue or insulin itself. The dual problems
and progressive nature of T2DM predict that the vast
majority of patients with this disorder will require combi-
nation therapy for glucose control and ultimately will
include the need for insulin supplementation. Because
T2DM may require insulin therapy (even initially in severe
cases), the use of insulin for treatment does not establish
whether a person has T1DM or T2DM. It is the underlying
disease pathology that determines disease classification.
Hence, the critical features of treatment include individ-
ualization of treatment, achievement of the recommended
goals, appropriate monitoring of glucose levels and the use
of team members like diabetes educators, nutritionists, the
primary care provider and the endocrinologist.
Although achieving the American Diabetic Association
(ADA) recommended targets (19) for glucose (and other
risk factors) is challenging, the process has been greatly
aided by the demonstration that it can be done and by the
availability of newer treatment options that have excellent
efficacy, safety and synergism of actions when used in
combination (20). The cardiologist should incorporate
strategies for intensive glucose control as a linear process.
This is remarkably analogous to the approach to the
treatment of dyslipidemias and hypertension. An initial
strategy of medical nutrition therapy is established as a
foundation, to which is added a progressive array of phar-
maceuticals designed to target the underlying mechanisms.
In diabetes, like the other disorders, monotherapy should be
used until goals are no longer reached or maintained,
followed by the addition of other agents that will have
synergistic or additive effects on glucose levels. When oral
agents are ineffective in combination, the use of insulin is
warranted and should be vigorously pursued in all insulin-
requiring diabetics. These general principles constitute what
should be a matter of growing importance to all cardiolo-
gists: optimal glucose control in persons with diabetes.
In summary, the BARI and EAST trials reemphasize the
very important role of diabetes in the progression of CHD
and make it abundantly apparent that cardiologists must
become much more knowledgeable about the pathophysi-
ology of diabetes and more persuasive in their own attitudes
and actions in reference to glycemic control in diabetics.
The analogy with hypertension and the dyslipidemias is
quite close. It required many years before cardiologists, as a
group, became convinced that fastidious control of blood
pressure and dyslipidemia was of great importance to the
long-term outcome.
Mechanisms to achieve greater involvement of cardiolo-
gists in diabetic therapy include systematically incorporating
information about the management of diabetics into cardi-
ology fellowship programs, emphasizing the importance of
close collaborative efforts among physicians and other health
care providers involved in diabetic management in specific
patients and featuring more prominently the role of diabetes
in a variety of educational formats available to the cardiol-
ogists, including a wide variety of meetings. The promul-
gation of guidelines, which includes the role of diabetic
control, has already commenced (21–23), but this requires
additional emphasis since treatment goals are usually not
specifically stated. Much more data are needed and are
accumulating at a rapid rate before optimum treatment of
diabetic cardiology patients can be established. However,
the currently available information makes a compelling
argument for cardiologist to become more educated about
diabetes and adopt an enthusiastic assertive attitude in
reference to glycemic control.
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